quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·2025d
PRRelease
Axovant Gene Therapies Ltd. logo

Axovant Announces Positive Six-Month Follow-Up Data From Second Cohort of SUNRISE-PD Phase 2 Trial of AXO-Lenti-PD Gene Therapy

AXGT· Axovant Gene Therapies Ltd.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • AXGT
    Axovant Gene Therapies Ltd.
    Health Care

Related

  • PR1990d
    Axovant Gene Therapies Announces Name Change to Sio Gene Therapies
  • PR1991d
    Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 Gene Therapy in Tay-Sachs and Sandhoff Diseases
  • PR2002d
    Axovant Gene Therapies to Present AXO-Lenti-PD Program Update During Virtual Parkinson’s Disease R&D Day on October 30, 2020
  • PR2004d
    Why Gastrointestinal (GI) Cancer Drugs Are Expected to See Significant Growth Over Next Few Years
  • PR2009d
    Axovant Gene Therapies to Host Virtual Parkinson’s Disease R&D Day on October 30, 2020
  • PR2022d
    Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM1 for GM1 Gangliosidosis
  • PR2023d
    Axovant Gene Therapies Strengthens Board of Directors and Announces New Chief Commercial Officer
  • PR2026d
    Axovant to Participate in Upcoming October Conferences and Provide AXO-Lenti-PD Program Update the Morning of October 6th
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022